Skip to main content
Publications
Boeri M, Marcek T, Chintakayala PK , Poulos C , Francis A, Langevin E, Balogh O, Petigara T, O’Connor J, Samant S. Preferences of nurses for attributes of pediatric hexavalent vaccines in the United Kingdom . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S313. doi: 10.1016/j.jval.2023.09.1653
Weibel D, de Luise C, Elbers R, van den Bor R, Martin I, Cid-Royo A, Plana E , Garcia de Albeniz Martinez X , Weinrib R , Yefimenko N, Poblador-Plou B, Marconi E, Barbieri E, Stona L, Swart KMA, Roy D, Hyeraci G, Bartolini C, Lupattelli A, Villalobos F, Kendrick K, Garg R, Rubino H, Eijkemans R, Sturkenboom M, Arana A . Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):173-4. doi: 10.1002/pds.5687
Levesque L, Johannes CB , Lecciones JA, Giamberardino H, Marcelon L, Cohen C, Rojas A, Bennett L , Khromava A. Post-authorization safety study: cohort event monitoring for CYD-TDV dengue vaccine (DNG15) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):592. doi: 10.1002/pds.5687
Ahmadizar F, Fortuny J , Cid-Royo A, Plana E , Weinrib R , Garcia Esteban R , Boric K , Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687
Mellott C, Jaworski R, Carrico J , Clinkscales M, Talbird S , Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568
Talbird S , Graham J , Anderson S , Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis . Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649
Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E , Garcia de Albeniz X , Weinrib R , Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, de Luise C, Arana A . VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results . Poster presented at the 2022 ICPE Conference; August 30, 2022. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2022 Sep 23; 31(S2):627-8. doi: 10.1002/pds.5518
Carrico J , Mellott C, Talbird S , Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium . Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J , Hicks K , Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster . Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Baker M, Jankosky C, Yih K, Gruber S, Li L, Cocoros N, Lipowicz H, Coronel-Moreno C, Feibelmann S, Lin N, McMahill-Walraven C, Menschik D, Selvan M, Selvam N, Tilney RC, Zichittella L, Lee G, Kawai AT . The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines . Poster presented at the 2017 Infectious Disease Week Conference; October 6, 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct; 4(Suppl 1):S464-5. doi: 10.1093/ofid/ofx163.1187
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J , Hicks K , Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster . Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.
Papanicolaou S, Kontodimas S, Syriopoulou E, Tsolia M, Theodoridou M, Kremastinou J, Tzanakaki G, Strutton D, Hwang S, Earnshaw SR . Clinical and economic benefits of national immunization with the 13-valent compared to 7- and 10-valent pneumococcal conjugate vaccines in Greece . Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A423-4.